Determination of stavudine, a new antiretroviral agent, in human plasma by reversed-phase high-performance liquid chromatography with ultraviolet detection.
A sensitive high-performance liquid chromatographic assay has been developed to determine the levels of a new antiretroviral agent, stavudine (2',3'-didehydro-3'-deoxythymidine, d4T), in human plasma. Didanosine (2',3'-dideoxyinosine, ddI) was used as the internal standard. The very selective sample pretreatment involved solid-phase extraction using silica gel columns. Chromatography was carried out on a mu Bondapak phenyl column, using a mobile phase of 0.005 M phosphate buffer (pH 6.8)-methanol (90:10, v/v) and ultraviolet detection at 265 nm. The method has been validated, and stability tests under various conditions have been performed. The detection limit is 10 ng/ml (using 500-microliters human plasma samples). The bioanalytical assay has been used in a single pharmacokinetic experiment in a rat to investigate the applicability of the method in vivo.
Burger
D M
DM
Department of Pharmacy, Slotervaart Hospital, Amsterdam, Netherlands.
Rosing
H
H
van Gijn
R
R
Meenhorst
P L
PL
van Tellingen
O
O
Beijnen
J H
JH
D000818:Animals; D000998:Antiviral Agents / Q000097:blood* / Q000493:pharmacokinetics; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D015224:Dideoxynucleosides / Q000097:blood* / Q000493:pharmacokinetics; D006801:Humans; D051381:Rats; D015203:Reproducibility of Results; D012190:Retroviridae; D013056:Spectrophotometry, Ultraviolet; D018119:Stavudine
D000998:Antiviral Agents; D015224:Dideoxynucleosides; D018119:Stavudine